Cullinan Therapeutics Inc. has provided an update on its corporate initiatives, emphasizing the advancement of its clinical-stage programs. The company is progressing with its CLN-978 program, a CD19xCD3 T cell engager, with ongoing enrollment for systemic lupus erythematosus and plans to initiate studies for rheumatoid arthritis and Sjögren's disease. Additionally, Cullinan is advancing its oncology pipeline, including the anticipated pivotal study results for zipalertinib, shared at ASCO 2025, with a potential NDA submission later in the year. The company maintains a robust financial position, with a cash runway extending into 2028. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。